A committed partner in the fight against malaria
Preface
Malaria is a highly preventable and treatable disease, and yet it remains one of the world’s deadliest, claiming over 1 million lives each year, most of them children under 5 years old. Every 30 seconds, a child dies of malaria.
The Roll Back Malaria Partnership was founded in response to the growing concern about the continuing and increasing burden of disease and death due to malaria, particularly in Africa where over 80% of the world’s malaria cases occur. Roll Back Malaria and its partners are convinced that the key to addressing the challenge of reducing the burden of malaria is an integrated approach that combines preventative measures, such as bed nets and indoor residual spraying, with improved access to effective anti-malaria drugs. These actors are committed to combating malaria on all fronts.
The strength of the Roll Back Malaria Partnership lies in the diverse capabilities and expertise of its individual partners, and, more important, in partners’ willingness to work together. From the outset, Novartis has worked in collaboration with government bodies, research institutes, and multilateral organizations to bring its antimalarial drug, Coartem® , to those who need it most. Since 2001, Novartis has delivered more than 280 million treatments of Coartem®. Achieving cure rates of over 95% even in areas of multi-drug resistance, this medicine has been an important component in the crusade to roll back malaria.
The Roll Back Malaria Partnership wishes to take this opportunity to express its heartfelt gratitude to Novartis for its remarkable commitment to bringing life-saving malaria treatments to those who need them most. Together, we can achieve a vision of a world in which medicines are available for all.
Professor Awa Marie Coll-Seck
Executive Director, Roll Back Malaria Partnership
